July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Challenges to the clinical application of iPSC- derived cornea
Author Affiliations & Notes
  • Kohji Nishida
    Ophthalmology, Osaka Univ School of Medicine, Suita, Japan
  • Footnotes
    Commercial Relationships   Kohji Nishida, Raymei,Inc. (S)
  • Footnotes
    Support  “Research Center Network for Realization of Regenerative Medicine - Highway Program for Realization of Regenerative Medicine” sponsered by JST and AMED
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2611. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kohji Nishida; Challenges to the clinical application of iPSC- derived cornea. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2611.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : We have been challenging to develop iPS cell-based therapy for corneal epithelial diseases (limbal stem cell deficiency; LSCD) and corneal endothelial diseases (bullous keratopathy, Fuchs corneal endothelial dystrophy etc.). To do so, it is key to develop the robust standardized protocol on which corneal epithelial progenitor cells and corneal endothelial cells are induced from human iPS cells. In the past, there were no techniques to induce human iPS cells to differentiate into corneal epithelial and endothelial cells and to then isolate those cells to create functional corneal and epithelium and endothelium. We first succeeded in induction of corneal epithelium from human iPS cells. In fact, we developed a 2D culture system to promote cell-autonomous differentiation of human iPS cells. The culture system can use human iPS cells to generate a 2D structure we named (a self-formed ectodermal autonomous multi-zone (SEAM)) consisting of 4 concentric zones of cells. Major groups of cells that comprise the eye during development (e.g. corneal epithelium, the retina, and the epithelium of the lens) are produced at specific locations in the SEAM. The current study successfully isolated corneal epithelial progenitor cells from the 3rd zone of the SEAM, and successfully generated functional corneal epithelium. Corneal epithelium produced from human iPS cells was transplanted in an animal model, where that corneal epithelium was therapeutically effective. These results greatly help to start the first-in-human clinical trial of iPS cell-derived corneal epithelium for LSCD. We also generated functional corneal endothelium from human iPS cells using our SEAM method.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×